Prognostic value of early lymphocyte dynamics during blinatumomab therapy in relapsed or refractory B-cell precursor acute lymphoblastic leukemia: A real-world retrospective study Authors: Seonghan Lee, Daehun Kwag, Gi June Min, Sung-Soo Park, Silvia Park, Sung-Eun Lee, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Hee-Je Kim, Chang-Ki Min, Seok-Goo Cho, Jae-Ho Yoon Published: 2026 ABSTRACT AbstractBackgroundBlinatumomab, a bispecific T-cell engager, mediates cytotoxicity through CD3+ T-cell activation and has shown efficacy in relapsed or refractory (R/R) B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Although T-cell expansion correlates with favorable outcomes, routine immunophenotyping is impractical in clinical settings.ObjectivesTo determine whether early changes in absolute lymphocyte count (ALC), a readily available laboratory marker, can serve as a surrogate indicator of therapeutic response and long-term survival in patients receiving blinatumomab.DesignA retrospective cohort study of adult patients with R/R BCP-ALL treated with blinatumomab.MethodsWe analyzed 162 adults with R/R BCP-ALL who received up to two cycles of blinatumomab. The primary outcome was complete remission (CR), and secondary outcomes included overall survival (OS). ALC change from day 1 to day 14 (ΔALC14) was calculated, and its association with outcomes was assessed using logistic and Cox regression models.ResultsOf the 162 patients, 106 (65.4%) achieved CR. ΔALC14 was significantly greater in responders than in non-responders (median 0.344 vs. 0.146 × 109/L; P < 0.001). A high ΔALC14 (≥0.100× 109/L) was independently associated with higher response rates (OR: 2.96; P=0.004) and longer OS (median 15.3 vs. 7.0 months; P=0.007). Multivariate analysis confirmed high ΔALC14 as an independent predictor of response and favorable OS. Subgroup analyses suggested that the association between high ΔALC14 and response was more evident in first salvage than in later salvage (OR 8.40 vs. 1.82), whereas its association with OS was more evident in second or later salvage (median OS 14.5 vs. 4.3 months; P=0.005).ConclusionEarly lymphocyte expansion during blinatumomab therapy, reflected by ΔALC14, is an independent predictor of treatment response. ALC monitoring may offer a simple, cost-effective tool for risk stratification.Keywords: B-cell precursor acute lymphoblastic leukemia, blinatumomab, lymphocyte, real-world evidence, bispecific antibody, bispecific T-cell engager Introduction Despite the high complete remission (CR) rate of up to 90% with intensive chemotherapy in adult patients with acute lymphoblastic leukemia (ALL), high relapse rates remain a significant challenge, even with allogeneic hematopoietic cell transplantation (allo-HCT).1–3 Post-relapse outcomes are particularly poor, demonstrating CR rates of 30-50% following conventional salvage chemotherapy and long-term overall survival (OS) rates falling below 20%.4–7 Recently developed immune-based therapeutic approaches have shown promising results as salvage and bridge therapy to allo-HCT, including bispecific T-cell engagers (BiTEs),8,9 chimeric antigen receptor T-cell therapy, 10 and antibody-drug conjugates.11,12 Blinatumomab, the first BiTE antibody construct, has demonstrated significant therapeutic efficacy in relapsed or refractory (R/R) B-cell precursor acute lymphoblastic leukemia (BCP-ALL). The agent’s antileukemic mechanism relies on a dual action: (1) T-cell-mediated cytolysis of BCP-ALL via binding to CD19 on B-cells and the CD3ε component of the T-cell receptor, and (2) facilitation of T-cell proliferation.13,14 In clinical trials, blinatumomab demonstrated superior OS and response rates compared to standard chemotherapy in Philadelphia chromosome (Ph)-negative BCP-ALL, 15 and also showed efficacy in Ph-positive BCP-ALL. 16 In light of these promising outcomes, the clinical indications for blinatumomab have been broadened to include measurable residual disease (MRD)-positive BCP-ALL,17,18 as well as use during the consolidation phase in patients who achieved MRD-negativity.19,20 Previous studies have identified several predictive factors for blinatumomab response. High leukemia burden, CRLF2-rearranged Ph-like ALL, and mutations in the CD19 epitope recognized by blinatumomab are known to be associated with poor treatment outcomes.21–23 Of particular interest is the potential role of lymphocytes and their kinetics in predicting response and survival outcomes, as the mechanism of action of blinatumomab is intrinsically linked to T-cell function and proliferative dynamics. Given its mechanism of action, whether blinatumomab confers clinical benefit in patients with markedly low pretreatment lymphocyte counts remains an area of ongoing investigation. Several studies suggest that although a low absolute lymphocyte count (ALC) at baseline does not necessarily impair treatment response, higher baseline CD8+ T-cell counts and a lower proportion of regulatory T cells are associated with improved response rates.24,25 Furthermore, patients who respond to blinatumomab demonstrate more robust T-cell expansion during treatment compared to non-responders, a phenomenon that is associated with improved survival outcomes.26,27 Although these findings provide meaningful insights, their clinical applicability remains limited due to the resource-intensive requirements of comprehensive lymphocyte subset profiling. While ALC encompasses heterogeneous lymphocyte populations beyond T cells and therefore represents an imperfect surrogate for T-cell-specific dynamics, it is a routinely available clinical parameter that may provide a pragmatic measure of early immune recovery. Nevertheless, whether early changes in ALC at defined timepoints during blinatumomab treatment, rather than static baseline measurements or detailed lymphocyte subset profiling, have independent predictive and prognostic value in real-world settings has not been systematically evaluated. Accordingly, this study aims to evaluate the long-term real-world outcomes of blinatumomab in adult patients with R/R BCP-ALL, focusing on the dynamic changes in routinely measured lymphocyte counts throughout the treatment course. Methods Study population We conducted a retrospective analysis of 162 consecutive adult patients (median age, 39.5 years; range, 19–79 years) with R/R BCP-ALL treated with blinatumomab at Seoul St. Mary’s Hospital, South Korea, between November 2016 and March 2024. Eligible patients were identified and their clinical data were collected through a review of electronic medical records, and follow-up data were collected through December 31, 2024. Patients were eligible if they were aged 19 years or older, had been diagnosed with R/R BCP-ALL, and received blinatumomab for salvage treatment. Patients who received blinatumomab for MRD elimination or as consolidation therapy were excluded. For patients with Ph-negative ALL, blinatumomab was administered as first- or later-line salvage therapy starting in 2016. In contrast, for those with Ph-positive ALL, it was further approved in 2019 and used exclusively as a later-line option after failure of two or more prior salvage tyrosine kinase inhibitors (TKIs). This study was approved by the Institutional Review Board of The Catholic University of Korea on May 30, 2025 (IRB No. KC25RISI0347). The requirement for written informed consent was waived due to the retrospective nature of the study involving only de-identified data and procedures that were conducted in accordance with the Declaration of Helsinki. The reporting of this study conforms to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement. 28 Treatment strategy As described in our previous studies, all patients with newly diagnosed ALL received induction chemotherapy using a modified hyper-CVAD (hyper-fractionated cyclophosphamide, vincristine, daunorubicin, and dexamethasone) on odd-numbered cycles, alternating with high-dose cytarabine plus mitoxantrone on even-numbered cycles. Allo-HCT was offered upon achieving CR after frontline chemotherapy, irrespective of MRD status.29–32 The standard blinatumomab protocol included a prephase of dexamethasone (10 mg intravenously every 12 hours for four days) to reduce leukemic burden and minimize the risk of cytokine release syndrome (CRS).33,34 Hydroxyurea or low-dose cytarabine was administered as needed to lower tumor burden, with the goal of reducing the white blood cell (WBC) count to <10 × 109/L. Blinatumomab was administered for two cycles, separated by a two-week treatment-free interval. Treatment was discontinued during the first cycle in patients who showed early disease progression or developed severe adverse events, including grade ≥3 CRS, tumor lysis syndrome (TLS), or serious infections. Only patients who achieved at least a partial response after the first cycle proceeded to the second cycle. Blinatumomab was administered at a dose of 9 μg/day during week 1 of the first cycle and escalated to 28 μg/day thereafter.35,36 Patients who achieved CR after two cycles were offered allo-HCT as early as possible. Patients who failed to respond to blinatumomab received salvage chemotherapy with high dose cytarabine, mitoxantrone, and etoposide. Since 2019, inotuzumab ozogamicin has been introduced as an additional salvage option and was prioritized for patients with high tumor burden, extramedullary relapse (EMR), or active graft-versus-host disease, in accordance with our previous findings.35,36 In other cases, blinatumomab remained the preferred initial salvage regimen. Definitions and patient assessment No formal sample size calculation was performed because of the retrospective nature of the study. Instead, all consecutive patients with R/R BCP-ALL who were treated with blinatumomab during the study period were included. Patients who received blinatumomab for at least two weeks without evidence of primary resistance were evaluated for treatment response at the end of each cycle. Responders were defined as those who achieved complete remission (CR) within 12 weeks of treatment initiation, regardless of the total number of cycles administered, while non-responders were defined as patients who failed to achieve CR, or who discontinued blinatumomab or died for any reason within the first two weeks of therapy. Daily complete blood count (CBC) data, including ALC and platelet count, were collected for each patient throughout the first treatment cycle. At our institution, WBC differential counts for patients with hematologic malignancies are performed by manual morphological examination by certified laboratory technologists on weekdays, whereas automated differential analysis is used primarily on weekends and holidays when manual staffing is unavailable. ALC was calculated as the product of the total white blood cell count and the lymphocyte proportion from the differential count. For manually reviewed peripheral blood smears, lymphoblasts were classified separately from mature lymphocytes, and only cells morphologically classified as lymphocytes were included in the lymphocyte fraction used to calculate ALC. Changes in ALC were further analyzed, based on the rationale that the CD3+ lymphocyte subpopulation tends to undergo substantial expansion in responders.26,27 For patients who discontinued blinatumomab during the first treatment cycle, CBC data were collected only on days when blinatumomab was actually administered. Each hematologic parameter and its longitudinal trend were compared between responder and non-responder groups from baseline (Day 0) through Day 28 of the first cycle. Statistical analysis The primary endpoint of this study was the response rate, defined as the achievement of CR. Secondary endpoints included overall survival (OS), defined as the time from the initiation of blinatumomab therapy to death from any cause, and cumulative incidence of relapse (CIR), defined among responders as the time from therapy initiation to relapse. Patients without an event were censored at the date of last confirmed follow-up. Differences in CBC parameters between responders and non-responders were analyzed using the nonparametric Mann–Whitney U test. For dichotomization of continuous variables without established clinical thresholds, optimal cutoffs were first estimated using the Youden index from receiver operating characteristic (ROC) analysis, and the nearest clinically interpretable round values were adopted for group assignment. For variables with commonly used clinical thresholds, such as peripheral blood and BM blast percentages, predefined cutoffs were applied. Response rates were compared between subgroups using logistic regression. OS was estimated via the Kaplan–Meier method and compared between subgroups using the log-rank test. CIR, accounting for death as a competing risk, was analyzed using Gray’s test. Candidate covariates for multivariable analyses were selected based on clinical relevance and univariate associations with each outcome, using a threshold of P < 0.150. These variables included age, sex, leukocyte count at diagnosis, prior allo-HCT, previous CR duration, extramedullary relapse, BM blast percentage, cytogenetic risk, prior salvage therapy, baseline peripheral blood blast percentage, and baseline platelet count. Collinearity among candidate variables was assessed using the variance inflation factor (VIF), and when substantial collinearity was present (VIF > 5), the clinically less relevant variable was excluded. The number of covariates in each final model was restricted to maintain a minimum of 10 events per variable (EPV), thereby reducing the risk of model overfitting. Logistic regression was employed for response rate analysis, Cox proportional hazards regression for OS, and Fine–Gray subdistribution hazard model for CIR. For ALC values missing at prespecified timepoints, the reason for missingness was reviewed. Values omitted despite ongoing treatment were estimated by linear interpolation using the nearest preceding and subsequent measurements. Patients who died before the relevant timepoint were excluded from the corresponding timepoint-specific analyses, as death represents a terminal event that precludes further biomarker assessment. For patients who discontinued blinatumomab because of adverse events or disease progression but had ALC values measured at the corresponding timepoints, the measured values were used in the primary analysis. A sensitivity analysis excluding patients who discontinued treatment early was also performed. Results Patient characteristics Of 172 potentially eligible patients, 10 were excluded due to MRD elimination or consolidation intent. The baseline characteristics of the remaining 162 patients are summarized in Table 1. Among them, 38 (23.5%) patients were primary refractory to induction chemotherapy, while 97 (59.9%) patients were in their first relapse and 27 (16.7%) had experienced two or more relapses. In terms of transplant history, 82 (50.6%) patients had relapsed following prior allo-HCT, while 80 (49.4%) had no history of prior allo-HCT. EMR was observed in 32 (19.7%) patients, of whom 12 (7.4%) had isolated EMR. A total of 103 (63.6%) patients had bone marrow (BM) blasts exceeding 50% at the time of initiating blinatumomab. Poor-risk cytogenetics were identified in 79 (48.8%) patients, of whom 45 (27.8%) had Ph-positive BCP-ALL. The median number of blinatumomab cycles administered was two (range, 1–5). Treatment was discontinued during or after the first cycle in 57 patients (35.2%) due to early disease progression, severe adverse events, or patient preferences. Additionally, five (3.1%) patients who were ineligible for or declined allo-HCT received up to three additional cycles as maintenance therapy. Regarding blinatumomab treatment sequence, it was administered as the first salvage therapy in 101 (62.3%) patients, as the second salvage in 23 (14.2%), and as the third or later salvage in 38 (23.5%) patients. Among the 61 patients who received blinatumomab as second or later salvage therapy, 18 (29.5%) had received intensive chemotherapy, 45 (73.8%) had received TKI-based therapy, and 7 (11.5%) had received inotuzumab ozogamicin; these categories were not mutually exclusive. Table 1.Baseline characteristics.ParametersN = 162 Age, median (range), yr 39.5 (19-79) < 40 yr, n (%)81 (50.0) ≥ 40 yr, n (%)81 (50.0) Sex Men, n (%)78 (48.1) Women, n (%)84 (51.9) Leukocyte count at diagnosis, median (range), x 10 9 /L 22 (0.1-552) < 30 x 109/L, n (%)91 (56.2) 30-100 x 109/L, n (%)38 (23.5) ≥ 100 x 109/L, n (%)33 (20.4) Relapse status Primary refractory, n (%)38 (23.5) 1st relapse, n (%)97 (59.9) ≥ 2nd relapse27 (16.7) Prior allo-HSCT Yes, n (%)82 (50.6) No, n (%)80 (49.4) Disease Site BMR alone, n (%)130 (80.2) EMR alone, n (%)12 (7.4) BMR + EMR, n (%)20 (12.3) BM blasts, median (range), % a 74.0 (1.0-99.0) < 20%, n (%)40 (24.7) 20-50%, n (%)19 (11.7) ≥ 50%, n (%)103 (63.6) Cytogenetic risk a Standard-risk, n (%)83 (51.2) Poor-risk, n (%)79 (48.8) Ph-positive, n (%)45 (27.8) KMT2A rearranged, n (%)8 (4.9) Hypoploidy, n (%)4 (2.5) Complex karyotype, n (%)22 (13.6) Number of cycles, median (range) 2 (1-5) 1, n (%)57 (35.2) 2, n (%)100 (61.7) ≥ 3, n (%)5 (3.1) Blinatumomab as 1st salvage101 (62.3) 2nd salvage23 (14.2) ≥ 3rd salvage38 (23.5) Salvage therapy prior to blinatumomab (n=61) Intensive regimen (MEC regimen)18 (29.5) TKI (dasatinib or ponatinib)45 (73.8) Inotuzumab ozogamicin7 (11.5)Abbreviations: HCT, hematopoietic cell transplantation; BM, bone marrow; BMR, bone marrow relapse; EMR, extramedullary relapse; MEC, mitoxantrone, etoposide, and high dose cytarabine; TKI, tyrosine kinase inhibitor.aAt the most recent available assessment before blinatumomab initiation. Baseline characteristics. Abbreviations: HCT, hematopoietic cell transplantation; BM, bone marrow; BMR, bone marrow relapse; EMR, extramedullary relapse; MEC, mitoxantrone, etoposide, and high dose cytarabine; TKI, tyrosine kinase inhibitor. aAt the most recent available assessment before blinatumomab initiation. Response to blinatumomab and realization of allo-HCT Figure 1 depicts the treatment flow and clinical response across blinatumomab cycles. Following the first cycle, 101 patients (62.3%) achieved CR. A total of 105 patients proceeded to the second cycle, including 13 who had achieved only partial response. Among the responders, nine patients did not continue to the second cycle due to relapse (n = 1), death (n = 2), or other reasons. After the second cycle, 89 patients were in CR, including 5 who newly achieved such responses during the second cycle. Twelve patients experienced relapse after the second cycle, leaving 83 (51.2%) patients with a sustained response prior to undergoing allo-HCT. Ultimately, 76 (46.9%) patients underwent allo-HCT in a blinatumomab-induced CR. Of the remaining patients, five received additional blinatumomab cycles as maintenance therapy instead of allo-HCT, one received best supportive care due to comorbidities, and one was lost to follow-up. Treatment flow and response to each cycle of blinatumomab. Abbreviations: CR, complete remission. Trends in absolute lymphocyte count in responders and non-responders Following up to two cycles, 106 (65.4%) patients achieved CR. ALC kinetics during the first cycle were assessed using 4,464 CBC results, of which 3,001 (67.2%) were obtained by manual differential counting and 1,463 (32.8%) by automated counting. This analysis revealed a distinct temporal pattern. ALC levels declined rapidly within the first 1-2 days, followed by a gradual increase until Day 7, when the blinatumomab dose was escalated from 9 μg/day to 28 μg/day. This escalation was associated with another transient decrease in ALC, followed by a sustained recovery phase continuing until the end of the cycle. Notably, the slope of ALC recovery was steeper in responders, presumably reflecting more vigorous T-cell expansion. However, absolute ALC values at specific timepoints during treatment did not clearly differentiate responders from non-responders (Figure 2). Given the steeper slope of ALC recovery and previous evidence of rapid CD3+ T-cell expansion, changes in ALC were analyzed across all timepoints for their association with response to blinatumomab, using Day 1 as the reference point. Day 14, corresponding to the midpoint of the first blinatumomab treatment cycle, was selected as the primary assessment timepoint for both clinical and analytical reasons. Clinically, this timepoint allows early risk assessment within the first treatment cycle before formal response evaluation. Analytically, ΔALC14 represented an early landmark at which statistically significant and consistent discrimination between responders and non-responders was observed. A total of 13 patients discontinued blinatumomab within 14 days of initiation; 6 discontinued due to disease progression and 7 due to adverse events. Two of these patients died within 14 days and therefore lacked post-baseline ALC data, whereas the remaining 11 patients had available ALC values. In addition, among patients who completed the full first cycle, 2 missed Day 14 ALC data because routine laboratory testing was omitted (Supplemental Table 1). The median ΔALC14 was 0.344 × 109/L in responders versus 0.146 × 109/L in non-responders (AUC = 0.671, P<0.001) (Figure 3). Responders typically exhibited an early decline in ALC followed by a gradual or oscillatory recovery pattern, with some showing steep lymphocyte expansion after dose escalation. In contrast, non-responders generally showed a sharp drop in ALC within the first few days and minimal recovery throughout the treatment course, indicating impaired T-cell dynamics. These findings support the potential utility of ALC kinetics as a surrogate marker of therapeutic response (Supplemental Figure 1). Platelet counts were consistently higher in responders compared to non-responders from baseline through the end of the first cycle (Supplemental Figure 2). Temporal trends in absolute lymphocyte count during the first cycle of blinatumomab, stratified by treatment response. ALC values are shown as absolute counts at each time point to illustrate the overall kinetic pattern during treatment, including the early nadir and subsequent recovery. Trends are compared between responders and non-responders. Abbreviations: AUC, area under the curve. Changes in absolute lymphocyte count from day 1 during the first cycle of blinatumomab, stratified by treatment response. ALC increment was calculated as the difference between ALC at each time point and ALC at Day 1, thereby accounting for inter-individual variability in baseline ALC. Abbreviations: AUC, area under the curve. Factors associated with response to blinatumomab For clinically practical risk stratification, ΔALC14 and baseline platelet count were each dichotomized based on optimal thresholds derived from ROC analysis. A high ΔALC14 (≥0.100 × 109/L; OR: 2.96, 95% CI: 1.43-6.13, P=0.004) and high baseline platelet counts (≥30 × 109/L; OR: 8.49, 95% CI: 3.32-21.7, P<0.001) were significantly associated with a higher response rate. In contrast, receipt of prior salvage therapy (OR: 0.44, 95% CI: 0.23-0.85, P=0.015) and high leukemic burden in peripheral blood, defined as PB blast ≥ 20% (OR: 0.23, 95% CI: 0.11-0.52, P<0.001) were associated with a significantly lower response rate, whereas a high BM blast ≥ 50% was not (OR: 0.75, 95% CI: 0.38-1.49, P = 0.412) (Supplemental Table 2). Given the clinical heterogeneity of the cohort with respect to Ph status and line of blinatumomab therapy, the association between ΔALC14 and response was examined separately within each subgroup. The association was directionally similar across Ph-positive (OR: 6.90, 95% CI: 1.53-31.0; P=0.012) and Ph-negative (OR: 2.19, 95% CI: 0.92–5.23; P=0.078) subgroups, although it reached statistical significance only in the former. The association was more pronounced in patients receiving blinatumomab as first salvage therapy (OR: 8.40, 95% CI: 2.09–33.8; P=0.003) than in those receiving it as second or later salvage therapy (OR: 1.82, 95% CI: 0.68–4.85; P=0.231). In the multivariate analysis, high ΔALC14 remained an independent predictor of response (OR: 2.50, 95% CI: 1.08–5.81; P=0.033), while high PB blast percentage was independently associated with a lower likelihood of response (OR: 0.29, 95% CI: 0.12–0.71; P=0.007) (Figure 4(A)). In the sensitivity analysis excluding patients who discontinued treatment before Day 14, ΔALC14 remained independently associated with response (OR: 3.28, 95% CI: 1.38–7.77; P=0.007). Multivariate analysis of factors influencing blinatumomab treatment outcomes. (A) Response to blinatumomab. (B) Overall survival. Abbreviations: ALC, absolute lymphocyte count; PB, peripheral blood; PLT, platelet; OR, odds ratio; CR, complete remission; Primary ref., Primary refractory; HR, hazard ratio. Overall survival and prognostic factors Among surviving patients, the median follow-up duration was 44.9 months (range, 9.3–95.5 months). The median OS of the entire cohort was 13.2 months (95% CI: 10.5–15.9), with a 4-year OS rate of 25.6% (95% CI: 18.6–33.1). Patients who responded to blinatumomab demonstrated significantly prolonged OS compared to non-responders (median OS: 23.7 vs. 4.3 months; 4-year OS rate: 34.3% vs. 11.6%, P<0.001) (Figure 5(A)). Most responders subsequently underwent allo-HCT, and they also showed improved post-transplantation OS compared to patients who received allo-HCT after other salvage therapies (median OS: 24.0 vs. 5.6 months; 4-year OS rate: 39.8% vs. 17.5%, P<0.001). High ΔALC14 was associated with longer median OS (15.3 vs. 7.0 months, P=0.007) (Figure 5(B)). The C-index for ΔALC14 was 0.594. Time-dependent AUC values were 0.712 at 3 months, 0.715 at 6 months, 0.621 at 12 months, and 0.574 at 24 months, indicating attenuation of prognostic discrimination over time (Supplemental Figure 4). Older age (≥40 years; 12.6% vs. 38.8%, P<0.001) and prior salvage therapy (18.8% vs. 30.4%, P=0.043) were also associated with inferior survival. Patients experiencing early relapse—defined as a CR duration of less than 18 months—had worse OS compared to those with late relapse or primary refractory disease (19.9% vs. 33.1%, P=0.016) (Supplemental Table 3). When stratified by Ph status, the difference in OS according to ΔALC14 was significant in Ph-positive ALL (median OS 16.6 vs. 4.0 months, P=0.004) but not in Ph-negative ALL (median OS 15.7 vs. 8.4 months, P=0.110). When stratified by line of blinatumomab therapy, the difference in OS was more pronounced in patients receiving blinatumomab as second or later salvage (median OS 14.5 vs. 4.3 months, P=0.005) than in those receiving it as first salvage (median OS 25.9 vs. 8.4 months, P=0.068) (Supplemental Figure 3). In the multivariate analysis, high ΔALC14 was independently associated with favorable OS (HR: 0.58, 95% CI: 0.38-0.89; P=0.013), along with high baseline platelet count (HR: 0.44, 95% CI: 0.27-0.72, P<0.001), while older age was associated with worse survival (HR: 1.99, 95% CI: 1.36-2.93; P<0.001) (Figure 4(B)). Sensitivity analysis yielded consistent results regarding the association between high ΔALC14 and OS (HR: 0.54, 95% CI: 0.35-0.84; P=0.006). Overall survival according to blinatumomab response and absolute lymphocyte parameters. (A) Overall survival stratified by response to blinatumomab. (B) Overall survival stratified by ΔALC14. (C) Overall survival stratified by ΔALC14 and ALC. Abbreviations: BLIN-R, blinatumomab responders; BLIN-NR, blinatumomab non-responders; ALC14, absolute lymphocyte count at day 14; ΔALC14, absolute lymphocyte count increment from day 1 to day 14. High and low ΔALC14 were defined as ≥ 0.100 × 109/L and < 0.100 × 109/L, respectively. Cumulative incidence of relapse in responders Among the 106 responders, the 4-year CIR was 48.8% (95% CI: 38.2-58.6). Early relapse, defined as a previous CR duration of less than 18 months, was associated with a significantly higher relapse rate (59.3% vs. 20.0%, P=0.019), whereas a history of prior allo-HCT was associated with a lower relapse rate (38.5% vs. 58.2%, P=0.040). Notably, ΔALC14 was not associated with the risk of relapse (Supplemental Table 4). In the multivariate analysis, both early relapse (HR: 2.86, 95% CI: 1.14-7.15, P=0.025) and prior allo-HCT (HR: 0.26, 95% CI: 0.10-0.66, P=0.005) remained statistically significant predictors of relapse. Discussion As the clinical indication for blinatumomab expands and its use increasingly shifts toward frontline therapy, a comprehensive understanding of its clinical characteristics—particularly predictive and prognostic factors—has become increasingly important. Several studies have underscored the prognostic relevance of baseline lymphocyte subset composition and its kinetics during blinatumomab treatment. Specifically, a high baseline proportion of CD45+ CD3+ CD8+ T cells and a low proportion of regulatory T cells have been associated with improved treatment response, whereas absolute lymphocyte or T-cell counts alone were found to be less informative.24,25 In addition, responders have consistently demonstrated marked T-cell proliferation in both R/R and MRD-positive settings, and greater T-cell expansion has been linked to deeper remission and prolonged survival outcomes.26,27 Although these findings provide valuable insights into the interplay between blinatumomab activity and T-cell dynamics, T-cell subset analysis is not routinely implemented in clinical practice to predict response or guide therapeutic decisions prior to or during blinatumomab treatment. To translate this insight into clinical practice, we analyzed longitudinal ALC patterns in responders and non-responders. The initial rapid decline in ALC likely reflects early-phase B-cell depletion, as previously reported by Zugmaier et al., 26 whereas the subsequent recovery may partly mirror treatment-induced T-cell expansion. Although total ALC remains an imperfect surrogate for T-cell-specific kinetics, the observed association between early ALC recovery and treatment response supports its potential value as a pragmatic marker of blinatumomab activity. Although ALC recovery was independently associated with OS, this association appeared to be driven largely by early survival, consistent with its role as a marker of short-term treatment sensitivity. This interpretation is consistent with the high relapse risk after initial remission, whereby later survival outcomes are likely shaped by subsequent relapse, transplantation, and additional salvage therapies rather than by early immune dynamics alone. The exploratory subgroup analyses suggest that the clinical meaning of ALC recovery may differ according to treatment context. In earlier salvage settings, ALC recovery appeared more closely related to treatment response, whereas in later-line settings, its association with survival may reflect the limited availability of subsequent effective therapies. The apparent difference by Ph status should also be interpreted in light of institutional treatment sequencing, because Ph-positive patients had uniformly received prior TKI-based salvage before blinatumomab. These observations are hypothesis-generating and should be interpreted with caution given the exploratory nature of the subgroup analyses and the limited sample size within each subgroup. We also evaluated established prognostic and predictive factors of blinatumomab in the R/R BCP-ALL setting. Multiple prior studies have identified low leukemia burden—defined by both BM blast and MRD—as a strong predictor of CR and OS.21,22,37 Our previous study with shorter follow-up similarly demonstrated that early relapse, EMR, and PB blast percentage were adverse prognostic indicators of blinatumomab outcomes. 35 However, in contrast to prior reports, baseline BM blast burden was not associated with CR rates or OS in the current analysis. This discrepancy may partly be explained by the fact that, in patients whose disease progression was confirmed based on peripheral blood findings alone, BM blast values reflected the most recently documented value before treatment initiation rather than the true BM leukemic burden at the time of blinatumomab administration, potentially attenuating the observed association. In this context, persistent PB blasts despite cytoreduction may represent a more immediate marker of active disease burden than archival BM blast values. The lack of adverse prognostic impact of EMR in our study may also be attributable to the introduction of inotuzumab ozogamicin in 2019, which was preferentially used in patients with EMR. Several limitations of this study should be acknowledged. The retrospective, single-center design carries inherent risks of selection bias, and formal sample size calculation was not performed, as patient enrollment was based on consecutive eligibility. Institutional practice patterns may also have influenced the results, including the use of blinatumomab after prior TKI-based salvage in all Ph-positive patients, the early referral to allo-HCT after blinatumomab-induced remission, and the preferential use of inotuzumab ozogamicin in selected patients with high tumor burden, EMR, or active GVHD after its introduction. The thresholds used to dichotomize continuous variables were derived from the study dataset itself, which may limit their generalizability; external validation in independent cohorts is warranted. Although potential confounders were adjusted for in multivariate analyses, residual confounding from unmeasured or incompletely captured variables cannot be excluded, including the potential influence of infection-related lymphopenia, post-initiation corticosteroid exposure, and CRS management on ALC kinetics. Missing CBC values, predominantly related to omitted laboratory testing, early mortality, or treatment discontinuation, may have introduced residual bias. Although omitted values during ongoing treatment were handled by linear interpolation and patients with early mortality were excluded from the corresponding timepoint-specific analyses, informative missingness cannot be entirely ruled out. However, sensitivity analyses excluding patients who discontinued treatment early yielded consistent results, partially mitigating this concern. Furthermore, some ALC measurements depended on automated differential counting, in which circulating lymphoblasts may be misclassified as lymphocytes; conversely, the relatively high proportion of manual differential counts at our institution may not reflect practice at centers relying predominantly on automated analysis with reflex smear review. Validation in cohorts from institutions with differing laboratory workflows would therefore be informative. Furthermore, serial flow cytometric assessment of lymphocyte subsets, including CD8+ T-cell counts, was not routinely available in this retrospective cohort. Future prospective studies incorporating serial immunophenotypic analyses are needed to determine whether ALC kinetics accurately reflects treatment-related CD8+ T-cell expansion. In addition, MRD response data were not incorporated into the present analyses, as next-generation sequencing and multiparametric flow cytometry-based MRD assessments were not routinely implemented at our institution until 2021 and 2022, respectively. Given the increasing recognition of MRD as a surrogate marker of deep therapeutic response, future prospective studies incorporating serial MRD assessment are warranted to determine whether early ALC kinetics correlates with MRD clearance. Lastly, as the therapeutic use of blinatumomab continues to shift toward earlier treatment settings—including MRD-positive CR and consolidation phases—the applicability of our principal finding in these frontline contexts remains to be clarified. Despite these limitations, our findings support the potential clinical relevance of early ALC elevation during blinatumomab therapy. Because ALC is routinely available, its early kinetics may offer a practical means of identifying patients at risk for blinatumomab resistance before formal response assessment. However, whether this information can support early risk-adapted therapeutic strategies should be tested prospectively rather than inferred from the present retrospective data. Furthermore, whether ALC kinetics carries similar predictive or prognostic value in the context of other T-cell-engaging therapies, including novel BiTE constructs, would also be of interest. Conclusion In this study, early lymphocyte expansion during blinatumomab therapy was associated with treatment response in patients with R/R BCP-ALL, consistent with the T-cell-engaging mechanism of blinatumomab. This association was particularly pronounced in patients receiving blinatumomab as first salvage therapy. In the second or later salvage setting, lymphocyte expansion may also be associated with overall survival, although this finding should be interpreted cautiously given the exploratory nature of the subgroup analysis. Supplemental material Supplemental Material - Prognostic value of early lymphocyte dynamics during blinatumomab therapy in relapsed or refractory B-cell precursor acute lymphoblastic leukemia: A real-world retrospective study Supplemental Material for Prognostic value of early lymphocyte dynamics during blinatumomab therapy in relapsed or refractory B-cell precursor acute lymphoblastic leukemia: A real-world retrospective study by Seonghan Lee, Daehun Kwag, Gi-June Min, Sung-Soo Park, Silvia Park, Sung-Eun Lee, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Hee-Je Kim, Chang-Ki Min, Seok-Goo Cho and Jae-Ho Yoon in Therapeutic Advances in Hematology. Acknowledgements We thank clinical research coordinator Mijue Kim, and our charge nurses Jeeyeon Yoon, Suk Heo, and Bomi Kim. The authors express their gratitude to the clinical staff of Catholic Hematology Hospital for their assistance in data collection and to the patients whose records contributed to this research. The authors would also like to thank the institutional review board for their oversight and guidance. Author contributions: JHY designed the analysis; DK, GJM, SSP, SP, SEL, BSC, KSE, YJK, HJK, CKM, and SGC acquired data; SL analyzed the data. JHY and SL contributed to the writing and editing of the manuscript. Funding: The authors received no financial support for the research, authorship, and/or publication of this article. The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. Supplemental material: Supplemental material for this article is available online. ORCID iDs Sung-Eun Lee https://orcid.org/0000-0002-9810-2050 Yoo-Jin Kim https://orcid.org/0000-0001-6653-2956 Jae-Ho Yoon https://orcid.org/0000-0002-2145-9131 Ethical considerations This study was approved by the Institutional Review Board of The Catholic University of Korea on May 30, 2025 (IRB No. KC25RISI0347). Consent to participate The requirement for written informed consent was waived due to the retrospective nature of the study involving only de-identified data and procedures that were conducted in accordance with the Declaration of Helsinki. Data Availability Statement The data supporting the findings of this study are not publicly available due to participant privacy concerns but are available from the corresponding author, JHY, upon reasonable request and with approval from the Institutional Review Board of The Catholic University of Korea.* References Associated Data Supplementary Materials Supplemental Material - Prognostic value of early lymphocyte dynamics during blinatumomab therapy in relapsed or refractory B-cell precursor acute lymphoblastic leukemia: A real-world retrospective study Supplemental Material for Prognostic value of early lymphocyte dynamics during blinatumomab therapy in relapsed or refractory B-cell precursor acute lymphoblastic leukemia: A real-world retrospective study by Seonghan Lee, Daehun Kwag, Gi-June Min, Sung-Soo Park, Silvia Park, Sung-Eun Lee, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Hee-Je Kim, Chang-Ki Min, Seok-Goo Cho and Jae-Ho Yoon in Therapeutic Advances in Hematology. Data Availability Statement The data supporting the findings of this study are not publicly available due to participant privacy concerns but are available from the corresponding author, JHY, upon reasonable request and with approval from the Institutional Review Board of The Catholic University of Korea.*